LOGIN  |  REGISTER
Recursion

Palatin Technologies to Report First Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on November 14, 2023

November 09, 2023 | Last Trade: US$1.19 0.02 -1.65

CRANBURY, N.J., Nov. 9, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter fiscal year 2024 operating results on Tuesday, November 14, 2023, before the open of the U.S. financial markets.

Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on November 14, 2023, at 11:00 a.m. ET. The conference call will include a review of the company's operating results and an update on programs under development.

Schedule for the Operating Results Press Release, Conference Call / Audio Webcast

Q1 Fiscal Year 2024 Results Press Release 

11/14/2023 at 7:30 a.m. ET

  

Q1 Fiscal Year 2024 Conference Call-Live 

11/14/2023 at 11:00 a.m. ET

     US Toll Free Dial-In Number:

1-888-506-0062

     International Dial-In Number: 

1-973-528-0011

     Participant Access Code:  

651512

  

Q1 Fiscal Year 2024 Conference Call-Replay

11/14/2023-11/28/2023

     US Toll Free Dial-In Number:   

1-877-481-4010

     International Dial-In Number: 

1-919-882-2331

     Participant Access Code:  

49457

The audio webcast and replay can be accessed by logging on to the "Investors-Webcasts" section of Palatin's website at http://www.palatin.com or by clicking here.

About Palatin

Palatin is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin's website at www.palatin.com and follow Palatin on Twitter at @PalatinTech.

Assertio

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page